Tin tức & Cập nhật
Xem bài viết Ung thư
Xem
Chỉ hiển thị Multimedia

Apalutamide for castration-resistant prostate cancer yields real-world results
25 Mar 2022
Patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) who have been initiated on apalutamide in a real-world setting appear to show prostate-specific antigen (PSA) response that is strong and consistent with that reported in clinical trials, as reported in a study.
25 Mar 2022

ADT after radiotherapy does not worsen MACE risk
22 Mar 2022
bởiTristan Manalac
Androgen deprivation therapy (ADT) does not seem to aggravate the likelihood of major adverse cardiovascular events (MACEs) in prostate cancer patients after curative radiotherapy (RT), according to a recent Singapore study.
22 Mar 2022







